Exact Mass: 489.11515119999996
Exact Mass Matches: 489.11515119999996
Found 73 metabolites which its exact mass value is equals to given mass value 489.11515119999996,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
4-Hydroxy duloxetine glucuronide
C24H27NO8S (489.14573020000006)
4-Hydroxy duloxetine glucuronide is a metabolite of duloxetine. Duloxetine (sold under the brand names Cymbalta, Ariclaim, Xeristar, Yentreve, Duzela) is a serotonin-norepinephrine reuptake inhibitor (SNRI) manufactured and marketed by Eli Lilly. It is effective for major depressive disorder and generalized anxiety disorder (GAD). (Wikipedia)
3-Benzyl-1-(1H-imidazol-4-ylmethyl)-4-(thien-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carbonitrile
Gemigliptin
Vemurafenib
C23H18ClF2N3O3S (489.07254120000005)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EC - B-raf serine-threonine kinase (braf) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2336 - Raf Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].
Vemurafenib
C23H18ClF2N3O3S (489.07254120000005)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EC - B-raf serine-threonine kinase (braf) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2336 - Raf Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].
O1-[2-(2-amino-4-oxo-3,4-dihydro-pteridin-6-yl)-1-(1,2,3-dihydroxy-propyl)-ethyl]-beta-D-glucopyranuronic acid
N-(4-Acetamidophenyl)indomethacin Amide
C27H24ClN3O4 (489.14552540000005)
Vemurafenib (PLX4032)
C23H18ClF2N3O3S (489.07254120000005)
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].
Cys Cys His Gln
Cys Cys Gln His
Cys His Cys Gln
Cys His Gln Cys
Cys Gln Cys His
Cys Gln His Cys
His Cys Cys Gln
His Cys Gln Cys
His Gln Cys Cys
Gln Cys Cys His
Gln Cys His Cys
Gln His Cys Cys
N-(4-acetamidophenyl)-Indomethacin amide
C27H24ClN3O4 (489.14552540000005)
BMS 214662
C471 - Enzyme Inhibitor > C2020 - Farnesyl Transferase Inhibitor
5-chloro-2-[2-[4-[(2-cyanoethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium methyl sulphate
C24H28ClN3O4S (489.1488958000001)
Talmetacin
C27H20ClNO6 (489.0979090000001)
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
3-BENZYL-1,4,5-TRIPHENYLIMIDAZOLIUM PERCHLORATE
C28H26ClN2O4 (489.15810060000007)
1-Octyl-2,3-dimethylimidazolium bis(trifluoromethanesulfonyl)imide
C15H25F6N3O4S2 (489.11906020000004)
3-(3-amino-3-oxopropyl)-2-[[1-methyl-2-(p-tolyl)-1H-indol-3-yl]azo]benzothiazolium chloride
C26H24ClN5OS (489.13900040000004)
(S)-AMINO-(3-NITRO-PHENYL)-ACETICACID
C21H22F3NO7S (489.10690180000006)
2-(4-METHYLUMBELLIFERYL)-α-D-N-ACETYLNEURAMINIC ACID SODIUM SALT
C21H24NNaO11 (489.12469940000005)
[(2R)-1-[6-(propan-2-yloxycarbonylamino)purin-9-yl]propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphinic acid
C18H28N5O9P (489.16245680000003)
Gemigliptin
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
PRX-07034 hydrochloride
C21H29Cl2N3O4S (489.12557340000006)
PRX-07034 hydrochloride is a highly selective and potent 5-HT6 receptor antagonist with a Ki= 4-8 nM and an IC50 of 19 nM. PRX-07034 can be used for the research of enhancing working memory and cognitive flexibility[1].
(2S,3S,4R,5R)-2-(5-tert-Butyl-1,3,4-oxadiazol-2-yl)-5-(6-(4-chloro-2-fluoro-anilino)purin-9-yl)tetrahydrofuran-3,4-diol
C21H21ClFN7O4 (489.13275080000005)
1-((1H-Imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile
4-Hydroxy Duloxetine b-D-Glucuronide
C24H27NO8S (489.14573020000006)
5-(benzenesulfonyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-ethylbenzenesulfonamide
C24H27NO6S2 (489.12797220000004)
N-[4-bromo-2-[[(2-hydrazinyl-2-oxoethyl)amino]-phenylmethyl]phenyl]-3-(4-morpholinyl)propanamide
[9-(4-Ethoxyphenyl)sulfonyl-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-(4-methylphenyl)methanone
C27H23NO6S (489.12460180000005)
2-[5-Methanesulfonylamino-2-(4-aminophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-n-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide
C19H22F3N5O5S (489.12936780000007)
Citicoline
C14H27N4O11P2+ (489.11515119999996)
Citicoline is an essential intermediate in the biosynthetic pathway of structural phospholipids in cell membranes, particularly phosphatidylcholine. Once absorbed, citicoline is widely distributed throughout the body, crosses the blood-brain barrier and reaches the central nervous system (CNS), where it is incorporated into the membrane and microsomal phospholipid fraction. Citicoline activates biosynthesis of structural phospholipids of neuronal membranes, increases brain metabolism, and acts upon the levels of different neurotransmitters. Thus, citicoline has been experimentally shown to increase norepinephrine and dopamine levels in the CNS. Owing to these pharmacological mechanisms, citicoline has a neuroprotective effect in hypoxic and ischemic conditions, decreasing the volume of ischemic lesion, and also improves learning and memory performance in animal models of brain aging. In addition, citicoline has been shown to restore the activity of mitochondrial ATPase and membrane Na+/K+ATPase, to inhibit activation of certain phospholipases, and to accelerate reabsorption of cerebral edema in various experimental models. Citicoline has also been shown to be able to inhibit mechanisms of apoptosis associated to cerebral ischemia and in certain neurodegeneration models, and to potentiate neuroplasticity mechanisms. Citicoline is a safe drug, as shown by the toxicological tests conducted, that has no significant systemic cholinergic effects and is a well tolerated product. (PMID: 17171187) [HMDB]. Citicoline is found in many foods, some of which are chives, black walnut, kohlrabi, and abiyuch. Citicoline is an essential intermediate in the biosynthetic pathway of structural phospholipids in cell membranes, particularly phosphatidylcholine. Once absorbed, citicoline is widely distributed throughout the body, crosses the blood-brain barrier and reaches the central nervous system (CNS), where it is incorporated into the membrane and microsomal phospholipid fraction. Citicoline activates biosynthesis of structural phospholipids of neuronal membranes, increases brain metabolism, and acts upon the levels of different neurotransmitters. Thus, citicoline has been experimentally shown to increase norepinephrine and dopamine levels in the CNS. Owing to these pharmacological mechanisms, citicoline has a neuroprotective effect in hypoxic and ischemic conditions, decreasing the volume of ischemic lesion, and also improves learning and memory performance in animal models of brain aging. In addition, citicoline has been shown to restore the activity of mitochondrial ATPase and membrane Na+/K+ATPase, to inhibit activation of certain phospholipases, and to accelerate reabsorption of cerebral edema in various experimental models. Citicoline has also been shown to be able to inhibit mechanisms of apoptosis associated to cerebral ischemia and in certain neurodegeneration models, and to potentiate neuroplasticity mechanisms. Citicoline is a safe drug, as shown by the toxicological tests conducted, that has no significant systemic cholinergic effects and is a well tolerated product. (PMID:17171187). N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics D002491 - Central Nervous System Agents > D018697 - Nootropic Agents
(2R,3R,4S,7S)-7-(2-bromo-5-hydroxyphenyl)-3-[(3R,4R)-3,4-dihydroxypentanoyl]oxy-7-methoxy-2,4-dimethylheptanoate
4-Amino-1-{5-O-[hydroxy({hydroxy[2-(trimethylazaniumyl)ethoxy]phosphoryl}oxy)phosphoryl]pentofuranosyl}pyrimidin-2(1H)-one
C14H27N4O11P2+ (489.11515119999996)
4-[(2-bromophenoxy)methyl]-N-[4-[(3,5-dimethyl-1-pyrazolyl)methyl]phenyl]benzamide
4-[[3-[(4-Chlorophenyl)sulfonylamino]-2-quinoxalinyl]amino]-1-piperidinecarboxylic acid ethyl ester
C22H24ClN5O4S (489.1237454000001)
N-(3-hydroxyphenyl)-2-[[4-methyl-5-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-triazol-3-yl]thio]acetamide
3-[[4-(1-benzotriazolyl)-1-piperidinyl]sulfonyl]-N-cyclopentylbenzenesulfonamide
C22H27N5O4S2 (489.15043820000005)
(E)-3-(5-bromo-2-methoxyphenyl)-N-[[4-(morpholin-4-ylmethyl)phenyl]carbamothioyl]prop-2-enamide
4-[3-[(3-chloro-4-fluoroanilino)-oxomethyl]-7-oxo-1H-pyrazolo[1,5-a]pyrimidin-5-yl]-1-piperidinecarboxylic acid tert-butyl ester
1-[(4-chlorophenyl)-oxomethyl]-N-[4-(1-piperidinylsulfonyl)phenyl]-3-piperidinecarboxamide
C24H28ClN3O4S (489.1488958000001)
2-[(5-anilino-1,3,4-thiadiazol-2-yl)thio]-N-[3-(1-piperidinylsulfonyl)phenyl]acetamide
C21H23N5O3S3 (489.09629680000006)
N-[[3-(4-carboxybutyl)-5-chloro-3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-7-yl]carbonyl]-L-phenylalanine
[(2R,3S,4R,5R)-5-[2-amino-5-[[[(1S,4S,5R)-4,5-dihydroxycyclopent-2-en-1-yl]amino]methyl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
C17H24N5O10P (489.12607340000005)
JNJ-42226314
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain[1].
3,4,5-trihydroxy-6-{[1,3,4,5-tetrahydroxy-1-(4-hydroxy-2-imino-1h-pteridin-6-yl)pentan-2-yl]oxy}oxane-2-carboxylic acid
Cytidine 5'-diphosphocholine sodium salt dihydrate
C14H27N4O11P2+ (489.11515119999996)
(2s,3s,4s,5r,6r)-3,4,5-trihydroxy-6-{[(1r,2s,3r,4r)-1,3,4,5-tetrahydroxy-1-(4-hydroxy-2-imino-1h-pteridin-6-yl)pentan-2-yl]oxy}oxane-2-carboxylic acid
2-(hydroxymethyl)-6-[(2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}-1h-indol-3-yl)oxy]oxane-3,4,5-triol
C20H27NO11S (489.1304752000001)
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}-1h-indol-3-yl)oxy]oxane-3,4,5-triol
C20H27NO11S (489.1304752000001)